FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204243583> ?p ?o ?g. }

• W3204243583 endingPage "1112" @default.
• W3204243583 startingPage "1108" @default.
• W3204243583 abstract "The second wave of COVID-19 pandemic was not only associated with a rapid and severe surge in the number of cases but also limited availability of recommended medicines. Baricitinib has been known to reduce recovery time in COVID-19 pneumonia in association with remdesivir. Tofacitinib, with limited evidence, was used in severe COVID-19 pneumonia based on its similarity of action with baricitinib.Data of all patients admitted to the COVID-19 intensive care unit in the month of April were accessed and analyzed. Data of patients who were on other immunomodulators, invasive ventilation, or suffering from end-stage organ diseases were excluded from the analysis.Out of 73 patients, data of 50 were analyzed. Twenty-five received tofacitinib and the other 25 were managed with standard of care. Age, comorbidities, and gender distribution between the two groups were similar. On day 7 of admission, the change in SpO2/FiO2 ratio was 1.26 ± 1 and 0.72 ± 1 in the tofacitinib group and control group, respectively. Similarly, a higher number of subjects in the control group showed worsening in the World Health Organization (WHO) ordinal scale (36 vs 12%, p = 0.01). The clinical objective improvement was similar in the two groups. The intubation rates in the tofacitinib group were significantly lower than that in the control group (32% vs 8%, p = 0.034).Tofacitinib, in this retrospective single-center experience, was found to be associated with reduced intubation rates and reduced worsening in the WHO ordinal scale. There was no difference in mortality in the two groups.Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, et al. Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience. Indian J Crit Care Med 2021;25(10):1108-1112." @default.
• W3204243583 created "2021-10-11" @default.
• W3204243583 creator A5015793050 @default.
• W3204243583 creator A5064223118 @default.
• W3204243583 creator A5064278147 @default.
• W3204243583 creator A5070578045 @default.
• W3204243583 creator A5073291293 @default.
• W3204243583 creator A5073819644 @default.
• W3204243583 creator A5089895466 @default.
• W3204243583 date "2022-06-21" @default.
• W3204243583 modified "2023-10-02" @default.
• W3204243583 title "Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience" @default.
• W3204243583 cites W2089785792 @default.
• W3204243583 cites W2413887177 @default.
• W3204243583 cites W2948262669 @default.
• W3204243583 cites W3015323620 @default.
• W3204243583 cites W3044087915 @default.
• W3204243583 cites W3092370030 @default.
• W3204243583 cites W3113196149 @default.
• W3204243583 cites W3117445270 @default.
• W3204243583 cites W3124796774 @default.
• W3204243583 cites W3134383271 @default.
• W3204243583 cites W3146610660 @default.
• W3204243583 cites W4210642183 @default.
• W3204243583 cites W4253054291 @default.
• W3204243583 doi "https://doi.org/10.5005/jp-journals-10071-23964" @default.
• W3204243583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34916741" @default.
• W3204243583 hasPublicationYear "2022" @default.
• W3204243583 type Work @default.
• W3204243583 sameAs 3204243583 @default.
• W3204243583 citedByCount "7" @default.
• W3204243583 countsByYear W32042435832022 @default.
• W3204243583 countsByYear W32042435832023 @default.
• W3204243583 crossrefType "journal-article" @default.
• W3204243583 hasAuthorship W3204243583A5015793050 @default.
• W3204243583 hasAuthorship W3204243583A5064223118 @default.
• W3204243583 hasAuthorship W3204243583A5064278147 @default.
• W3204243583 hasAuthorship W3204243583A5070578045 @default.
• W3204243583 hasAuthorship W3204243583A5073291293 @default.
• W3204243583 hasAuthorship W3204243583A5073819644 @default.
• W3204243583 hasAuthorship W3204243583A5089895466 @default.
• W3204243583 hasBestOaLocation W32042435831 @default.
• W3204243583 hasConcept C126322002 @default.
• W3204243583 hasConcept C2776376669 @default.
• W3204243583 hasConcept C2777575956 @default.
• W3204243583 hasConcept C2777914695 @default.
• W3204243583 hasConcept C2778716859 @default.
• W3204243583 hasConcept C2778886723 @default.
• W3204243583 hasConcept C42219234 @default.
• W3204243583 hasConcept C71924100 @default.
• W3204243583 hasConceptScore W3204243583C126322002 @default.
• W3204243583 hasConceptScore W3204243583C2776376669 @default.
• W3204243583 hasConceptScore W3204243583C2777575956 @default.
• W3204243583 hasConceptScore W3204243583C2777914695 @default.
• W3204243583 hasConceptScore W3204243583C2778716859 @default.
• W3204243583 hasConceptScore W3204243583C2778886723 @default.
• W3204243583 hasConceptScore W3204243583C42219234 @default.
• W3204243583 hasConceptScore W3204243583C71924100 @default.
• W3204243583 hasIssue "10" @default.
• W3204243583 hasLocation W32042435831 @default.
• W3204243583 hasLocation W32042435832 @default.
• W3204243583 hasLocation W32042435833 @default.
• W3204243583 hasOpenAccess W3204243583 @default.
• W3204243583 hasPrimaryLocation W32042435831 @default.
• W3204243583 hasRelatedWork W1529221860 @default.
• W3204243583 hasRelatedWork W1877883789 @default.
• W3204243583 hasRelatedWork W2099369673 @default.
• W3204243583 hasRelatedWork W2115378696 @default.
• W3204243583 hasRelatedWork W2316236384 @default.
• W3204243583 hasRelatedWork W2366973680 @default.
• W3204243583 hasRelatedWork W2474749474 @default.
• W3204243583 hasRelatedWork W3105902992 @default.
• W3204243583 hasRelatedWork W4230988655 @default.
• W3204243583 hasRelatedWork W4238257640 @default.
• W3204243583 hasVolume "25" @default.
• W3204243583 isParatext "false" @default.
• W3204243583 isRetracted "false" @default.
• W3204243583 magId "3204243583" @default.
• W3204243583 workType "article" @default.